President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Eli Lilly’s stock fell by 2.3% to close at 4:35 PM ET in after-hours trading, while Novo Nordisk’s American depositary receipts saw a decrease of 1.7%. This development came as a surprise to investors ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

We had not assumed this proposed rule would pass, and we continue to think Novo and Lilly will gain Medicare obesity drug coverage via overlapping indications with time, such as Zepbound’s ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on curbing government spending.

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

The Centers for Medicare and Medicaid Services issued ... $620 and maintaining our DKK 640/$89 fair value estimate for Novo Nordisk. We had not assumed this proposed rule would pass, and we ...